These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34589947)

  • 1. Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by
    Ruppert AM; Beau-Faller M; Debieuvre D; Ouafik L; Westeel V; Rouquette I; Mazières J; Bringuier PP; Monnet I; Escande F; Ricordel C; Merlio JP; Janicot H; Lemoine A; Foucher P; Poudenx M; Morin F; Langlais A; Souquet PJ; Barlesi F; Wislez M
    JTO Clin Res Rep; 2020 Sep; 1(3):100052. PubMed ID: 34589947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations.
    Lei L; Wang WX; Yu ZY; Liang XB; Pan WW; Chen HF; Wang LP; Fang Y; Wang M; Xu CW; Fang MY
    Transl Oncol; 2020 Feb; 13(2):329-335. PubMed ID: 31881505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy.
    Gu G; Liu C; Zhu X; Yang Y; Song S; Zhao Y; Sun G
    J Cancer Res Clin Oncol; 2024 Sep; 150(9):413. PubMed ID: 39244518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study.
    Tamiya Y; Matsumoto S; Zenke Y; Yoh K; Ikeda T; Shibata Y; Kato T; Nishino K; Nakamura A; Furuya N; Miyamoto S; Kuyama S; Nomura S; Ikeno T; Udagawa H; Sugiyama E; Nosaki K; Izumi H; Sakai T; Hashimoto N; Goto K
    Lung Cancer; 2023 Feb; 176():103-111. PubMed ID: 36634571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With
    Wu SG; Liao WY; Su KY; Yu SL; Huang YL; Yu CJ; Chih-Hsin Yang J; Shih JY
    JTO Clin Res Rep; 2021 Feb; 2(2):100140. PubMed ID: 34589991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prognostic Effect of
    Wahl SGF; Dai HY; Emdal EF; Berg T; Halvorsen TO; Ottestad AL; Lund-Iversen M; Brustugun OT; Førde D; Paulsen EE; Donnem T; Andersen S; Grønberg BH; Richardsen E
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS mutated Non-Small Lung Carcinoma: A Real World Context from the Indian subcontinent.
    Batra U; Nathany S; Sharma M; Bp A; Jose JT; Singh H; Mattoo S; Mehta A
    Cancer Med; 2023 Feb; 12(3):2869-2874. PubMed ID: 36069080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomes.
    Sato K; Akamatsu H; Koh Y; Ogawa K; Isa SI; Ando M; Tamiya A; Kubo A; Kitagawa C; Kawaguchi T; Yamamoto N
    BMC Cancer; 2022 Nov; 22(1):1148. PubMed ID: 36348317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.
    Spira AI; Tu H; Aggarwal S; Hsu H; Carrigan G; Wang X; Ngarmchamnanrith G; Chia V; Gray JE
    Lung Cancer; 2021 Sep; 159():1-9. PubMed ID: 34293517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Implication of
    Noordhof AL; Swart EM; Damhuis RAM; Hendriks LEL; Kunst PWA; Aarts MJ; van Geffen WH
    JTO Clin Res Rep; 2023 Sep; 4(9):100543. PubMed ID: 37674812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes and prognostic contributors in patients with
    Burns EA; Ensor JE; Hsu J; Thomas JS; Olsen RJ; Bernicker EH
    J Thorac Dis; 2021 Aug; 13(8):4785-4796. PubMed ID: 34527319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Characteristics and Outcomes in Advanced
    Lee J; Tan AC; Zhou S; Yoon S; Liu S; Masuda K; Hayashi H; Batra U; Kim DW; Goto Y; Tan SH; Wu YL; Lee DH; Tan DSW; Ahn MJ
    JTO Clin Res Rep; 2022 Jan; 3(1):100261. PubMed ID: 35024639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of distinct types of
    Jia Y; Jiang T; Li X; Zhao C; Zhang L; Zhao S; Liu X; Qiao M; Luo J; Shi J; Yang H; Wang Y; Xi L; Zhang S; Gao G; Su C; Ren S; Zhou C
    Oncol Lett; 2017 Dec; 14(6):6525-6532. PubMed ID: 29163686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissecting the Clinical Characteristics and Treatment Outcomes Correlates of
    Jing Y; Cheng R; Zeng H; Huang Q; He D; Sun J; Tian P; Li Y
    Int J Gen Med; 2024; 17():4507-4517. PubMed ID: 39386149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
    Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
    Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment.
    Sun Y; Li Z; Jian H; Xia L; Lu S
    J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and prognostic value of the
    Liu SY; Sun H; Zhou JY; Jie GL; Xie Z; Shao Y; Zhang X; Ye JY; Chen CX; Zhang XC; Zhou Q; Yang JJ; Wu YL
    Biomark Res; 2020; 8():22. PubMed ID: 32607238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
    Zhao D; Li H; Mambetsariev I; Mirzapoiazova T; Chen C; Fricke J; Kulkarni P; Villaflor V; Arvanitis L; Hamilton S; Afkhami M; Pillai R; Armstrong B; Erhunmwunsee L; Massarelli E; Sattler M; Amini A; Salgia R
    Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.